Published in Medicine and Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Affymax, Inc.
Report 1: Affymax, Inc. (Nasdaq:AFFY) announced that it plans to initiate Phase 3 clinical studies with Hematide(TM) in chronic renal failure patients following recent discussions with the United States Food and Drug Administration (FDA) on the design of the Phase 3 clinical trial program. Hematide is the company's lead drug in development for the treatment of anemia.
"Following meetings with the FDA, we believe we are well positioned to take advantage of the most...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly